
Roche

Roche

2016 results

London, 01 February 2017

This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this presentation, among others:

1 pricing and product initiatives of competitors;
2 legislative and regulatory developments and economic conditions;
3 delay or inability in obtaining regulatory approvals or bringing products to market;
4 fluctuations in currency exchange rates and general financial market conditions;
5 uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side-effects of pipeline or marketed products;
6 increased government pricing pressures;
7 interruptions in production;
8 loss of or inability to obtain adequate protection for intellectual property rights;
9 litigation;
10 loss of key executives or other employees; and
11 adverse publicity and news coverage.

Any statements regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that Roche’s earnings or earnings per share for this year or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of Roche.

For marketed products discussed in this presentation, please see full prescribing information on our website www.roche.com

Group

Severin Schwan

Chief Executive Officer

2016 performance

Outlook

2016: Targets fully achieved

Targets for 2016		*FY 2016*	
Group sales growth[1]	Low to mid-single digit	**+4%**	✓
Core EPS growth[1]	Ahead of sales growth	**+5%**	✓
Dividend outlook	Further increase dividend in Swiss francs[2]	**CHF 8.20**	✓

[1] At constant exchange rates (CER); [2] 2016 dividend as proposed by the Board of Directors

2016: Good sales growth in both divisions

	2016 CHFbn	2015 CHFbn	Change in % CHF	Change in % CER
Pharmaceuticals Division	**39.1**	37.3	**5**	**3**
Diagnostics Division	**11.5**	10.8	**6**	**7**
Roche Group	**50.6**	48.1	**5**	**4**

CER=Constant Exchange Rates

2016: Sales growth for fifth consecutive year



All growth rates at Constant Exchange Rates (CER)

2016: All regions contributed to sales growth



All growth rates at Constant Exchange Rates (CER)

2016: Building the base for future growth

New Molecular Entities: Launches and key read-outs

Launches	• Tecentriq in 2/3 line bladder & lung (US) • Alecensa in 2/3 line ALK+ lung (US) • Cotellic+Zelboraf in BRAFmut melanoma (US, EU) • Gazyva in R/R FL (US) • Venclexta/Venclyxto in 17p del CLL (US, EU)
Positive key read-outs	• Gazyva in 1L iNHL: GALLIUM (interim analysis) • Emicizumab in inhibitor patients: HAVEN1 • Actemra in Giant Cell Arteritis: GiACTA • Ocrevus in Multiple Sclerosis: filed in US and EU
Diagnostics	• Launch of cobas e 801

Roche significantly advancing patient care
Recognition for innovation 2013-present

14 *Breakthrough Therapy Designations*

Rank	Company	#
1	**Roche**	**14**
2	Novartis	11
3	BMS	10
3	Merck	10
4	AbbVie	7
4	Pfizer	7

Year	Molecule
2016	***Actemra*** *(Giant cell arteritis)*
	Alecensa *(1L ALK+ NSCLC)*
	Ocrevus *(PPMS)*
	Venclexta *(AML)*
	Venclexta + Rituxan *(R/R CLL)*
2015	***Actemra*** *(Systemic sclerosis)*
	Tecentriq *(NSCLC)*
	Venclexta *(R/R CLL 17p del)*
	Emicizumab*/ACE 910 (Hemophilia A)*
2014	***Esbriet*** *(IPF)*
	Lucentis *(Diabetic retinopathy)*
	Tecentriq *(Bladder)*
2013	***Alecensa*** *(2L ALK+ NSCLC)*
	Gazyva *(1L CLL)*

Source: http://www.focr.org/breakthrough-therapies as of 20 January 2017; PPMS=Primary Progressive Multiple Sclerosis; CLL=Chronic Lymphocytic Leukemia; NSCLC=Non-Small Cell Lung Cancer; IPF=Idiopathic Pulmonary Fibrosis

2016: Strong Core operating profit & stable margin



CER=Constant Exchange Rates

2016: Strong Core EPS growth



All growth rates at Constant Exchange Rates (CER)

2016: Dividend further increased



Payout ratio calculated as dividend per share divided by Core earnings per share (diluted); 2016 dividend as proposed by the Board of Directors;
Note: For 1995, a special dividend was paid out to mark F. Hoffmann-La Roche's 100th anniversary in 1996

2016 performance

Outlook

Launch of new medicines at a record high



2017: Sales and Core EPS guidance

Sales	Core EPS
Low to mid single digit	*Broadly in line with sales*



Allows for:
- Tamiflu generics
- Biosimilars
- APHINITY outcomes

Allows for:
- Tamiflu generics
- Biosimilars
- APHINITY outcomes
- PSI*

All growth rates at Constant Exchange Rates (CER)
*PSI=Past Service Income 2016

2017: Another important year for our pipeline

Key read-outs



Outcome studies are event-driven: timelines may change

2017 outlook

Group sales growth[1]	Low to mid-single digit
Core EPS growth[1]	Broadly in line with sales growth
Dividend outlook	Further increase dividend in Swiss francs

[1] At Constant Exchange Rates (CER)

Pharmaceuticals Division

Daniel O'Day

CEO Roche Pharmaceuticals

2016 results

Innovation

Outlook

2016: Pharma sales

Solid growth in Europe, International and US

	2016 CHFm	2015 CHFm	Change in % CHF	Change in % CER
Pharmaceuticals Division	**39,103**	**37,331**	**5**	**3**
United States	18,594	17,616	6	3
Europe	9,159	8,734	5	4
Japan	3,711	3,224	15	1
International	7,639	7,757	-2	4

CER=Constant Exchange Rates

2016: Pharma Division

Core operating profit growth faster than sales

	2016 CHFm	2016 % sales
Sales	**39,103**	**100.0**
Royalties & other op. inc.	1,944	5.0
Cost of sales	-8,175	-20.9
M & D	-6,362	-16.3
R & D	-8,588	-22.0
G & A	-1,013	-2.6
Core operating profit	**16,909**	**43.2**

2016 vs. 2015
CER growth



+5% in CHF

CER=Constant Exchange Rates

2016: Strong sales performance with increasing contribution from new launches



Absolute values and growth rates at Constant Exchange Rates (CER)

2016: New oncology products off to a good start



- Strong uptake of Perjeta and Kadcyla
- Growth of Herceptin due to longer treatment

- Growth impacted by decline in the US and Japan

- Gazyva in R/R iNHL (GADOLIN) off to a good start
- Gazyva in 1L iNHL (GALLIUM) filed in the EU

- Increased competition

- Cotellic+Zelboraf gaining market share in 1L and 2L

- US: 2L bladder launch off to a very strong start
- US: 1L bladder PDUFA date set for April 30
- US: Gaining share in 2/3L lung (all-comers label)

- US: Launch in 2L off to a very strong start
- BTD for 1L granted based on J-ALEX; ALEX data in H1

CER=Constant Exchange Rates
2016 Oncology sales: CHF 24.8bn; CER growth +4%

HER2 franchise: Growth driven by Perjeta



HER2 franchise Q4 2016

- Perjeta (+14%): Strong demand driven by EU, International and Japan
- Herceptin (0%): Developed markets saturated in metastatic indications
- Kadcyla (+2%): Growth remains driven by International and Japan

Outlook 2017

- APHINITY (adj BC) expected in Q1 2017
- Herceptin: Further SC conversion
- Perjeta: Further increasing penetration

CER=Constant Exchange Rates

Avastin: International growth offsets performance in developed markets



Avastin Q4 2016

- International (+13%): growth driven by China (1L lung) and LATAM
- EU (-4%): Strong growth in Germany, breast indication delisted in France
- US (-10%): Increased competition in 1/2L lung, 340B impact
- Japan (-5%): Impacted by mandatory price cut in April

Outlook 2017

- Continued uptake in ovarian and cervical
- Mesothelioma: Filing underway

CER=Constant Exchange Rates

Immunology franchise growing above CHF 7bn annualised, further launches expected in 2017



Immunology Q4 2016

Xolair (+8%)

- Allergic asthma & chronic idiopathic urticaria driving growth
- US pediatrics launch on-going; only biologic approved for children

MabThera/Rituxan (0%)

- Continues to grow in rheumatoid arthritis and vasculitis (GPA and MPA)

CER=Constant Exchange Rates; BTD=breakthrough therapy designation

Actemra/RoActemra: Strong growth driven by SC formulation and 1L monotherapy



Actemra Q4 2016

- US (+11%): Increasing SC uptake
- EU (+14%): Increasing monotherapy market share, also in 1L
- International (+22%): Growth driven by LATAM, Asia Pacific, EMEA

Outlook 2017

- Increasing 1L monotherapy leadership
- US/EU approval in giant cell arteritis (2nd BTD and priority review for Actemra)

CER=Constant Exchange Rates; IV=intravenous; SC=subcutaneous

Esbriet: Continue to target mild to moderate patient populations



Esbriet Q4 2016

- Market leadership in the US and EU5
- US (+19%): Growth driven by continued penetration into moderate and severe patient segments
- EU (-4%): Overall strong market leadership in all EU5 markets, increased competition

Outlook 2017

- Increased promotional support
- Increased investments in patient education

CER=Constant Exchange Rates

2016 results

Innovation

Outlook

2016: Key late-stage news flow

	Compound	Indication	Milestone	
Regulatory	**Gazyva**	Rituxan-refractory iNHL	US/EU approval	✓
	Venclexta	R/R CLL with 17p deletion	US approval	✓
	Ocrevus	RMS/PPMS	US/EU filing	✓
	Tecentriq	Bladder cancer	US approval	✓
	Tecentriq	2/3L NSCLC (all-comers)	US approval	✓
	Alecensa	2L ALK+ NSCLC	EU CHMP opinion	✓
Phase III readouts*	**lebrikizumab**	Severe asthma	Ph III LAVOLTA I/II	✗
	Tecentriq	2/3L NSCLC	Ph III OAK	✓
	Gazyva	1L aNHL	Ph III GOYA	✗
	Gazyva	1L FL (iNHL)	Ph III GALLIUM	✓
	Perjeta + Herceptin	Adjuvant HER2+ BC	Ph III APHINITY	Q1 2017
	Actemra	Giant cell arteritis	Ph III GiACTA	✓
	Alecensa	1L ALK+ NSCLC	Ph III ALEX	early 2017
Phase II readouts*	**lebrikizumab**	Atopic dermatitis	Ph II TREBLE, ARBAN	✓
	Tecentriq	Bladder cancer	Ph II IMvigor210 (1L)	✓
	Tecentriq + Avastin	1L Renal cancer	Ph II IMmotion150	ASCO GU
	Venclexta + Rituxan	R/R FL (iNHL)	Ph II CONTRALTO	✓
	Venclexta + Rituxan/Gazyva	1L aNHL	Ph II CAVALLI	✓

Emicizumab in hemophilia A inhibitor patients

Phase III HAVEN 1 met all endpoints

FDA BTD

HAVEN 1

Primary endpoint

- Significant reduction in number of bleeds[1]

Secondary endpoints included

- Significant reduction in number of bleeds in intra-patient comparison in people who had received prior bypassing agent prophylaxis

Safety profile and sub-cut administration

- Future trials to explore less frequent dosing
- Most common adverse events were injection site reactions, consistent with prior studies



[1] The study showed a statistically significant reduction in the number of bleeds over time in people treated with emicizumab prophylaxis compared to those receiving no prophylactic treatment. Emicizumab and its uses are investigational and have not been approved by the US Food and Drug Administration. Efficacy and safety have not been established. The information presented should not be construed as a recommendation for use. The relevance of findings in preclinical studies to humans is currently being evaluated.

Gazyva in 1L FL (iNHL)

34% risk reduction of disease progression

Roche

American Society of Hematology
Helping hematologists conquer blood diseases worldwide
San Diego, 3-6 Dec

	Rituxan + chemo (n=601)	Gazyva + chemo (n=601)
PFS by INV		
Pts with event, n (%)	144 (24.0)	101 (16.8)
HR	**0.66; p=0.001**	
Event-free at 3 yrs (%)	73.3	80.0
PFS by IRC		
Pts with event, n (%)	125 (20.8)	93 (15.5)
HR	**0.71; p=0.014**	
Event-free at 3 yrs (%)	77.9	81.9
OS		
HR	0.75; p=0.21	
Time to new treatment		
HR	0.68; p=0.009	

PFS by INV



GALLIUM phase III results presented at ASH:

- Primary endpoint met at interim analysis (median observation time of 35 months)
- Investigator assessed PFS HR expected to translate to a 1.5x longer mPFS (9 years instead of 6 years)
- Gazyva potentially new standard of care in 1L FL

Marcus R. *et al.*, ASH 2016; FL=follicular lymphoma; R=Rituxan; G=Gazyva; PFS=progression free survival; INV=investigator; IRC=independent review committee; HR=hazard ratio; OS=overall survival; Data cut-off: January 31, 2016

Tecentriq in 1L bladder cancer

PDUFA date set for April 30th



Extensive phase III program on-going

- Phase III trial **IMvigor211**: Tecentriq mono in 2L+ to read out in mid 2017
- Phase III trial **IMvigor130**: Tecentriq mono and combo with gem/plat in 1L to read out in 2019
- Phase III trial **IMvigor010**: Tecentriq mono in adjuvant to read out post 2019

MIBC=muscle invasive bladder cancer; mUBC=metastatic urothelial bladder cancer;
Patient numbers: Roche internal estimates (Mar 2014)

CIT: 10 CIT NMEs in the clinic besides Tecentriq

Multifold approaches across different tumor phenotypes



CIT=cancer immunotherapy; 1) Dual roles in T eff activation and T reg inhibition suggest aOX40 activity in both desert and inflamed phenotypes; IND=new investigational drug application; *PCV=personalised cancer vaccine in collaboration with BioNTech; tba=to be announced

CIT portfolio update

7 NMEs with mono & combo read-out in 2017



CIT=cancer immunotherapy; NME=new molecular entity; * Note: Timelines indicate first safety and/or efficacy readouts; Outcome studies are event driven, timelines may change.

CIT portfolio update: Lung cancer



			Study read-out*	Endpoints
IMpower150	1L NSCLC (non-sq)	Tecentriq + carbo/pac +/- Avastin	2017	PFS and OS
IMpower130	1L NSCLC (non-sq)	Tecentriq + carbo + nab-pac	2018	PFS and OS
IMpower131	1L NSCLC (sq)	Tecentriq + carbo + pac/nab-pac	2018	PFS and OS
IMpower132	1L NSCLC (non-sq)	Tecentriq + cis/carbo + pem	2018	PFS and OS
IMpower133	1L SCLC	Tecentriq + carbo + etoposide	2018	PFS and OS
IMpower110	1L Dx+ NSCLC	Tecentriq	2019	PFS and OS
IMpower010	Adj NSCLC	Tecentriq	2020	DFS

CIT=cancer immunotherapy; *Note: Outcome studies are event driven, timelines may change; carbo=carboplatin; pac=paclitaxel; nab-pac=nab-paclitaxel; cis=cisplatin; pem=pemetrexed; PFS=progression free survival; OS=overall survival; Pao & Girard. Lancet Oncol 2011; Johnson, et al. ASCO 2013

MORPHEUS: Novel CIT platform

Fast & efficient combo development



Multi-indication	Multi-basket	Randomised	Longitudinal	Adaptable
Indication specific umbrella protocol with SOC control arm	Biomarker defined subgroups for personalised healthcare	Faster and more confident decisions; potential for accelerated approval	At disease progression patients can reenter other combinations	Fast-track opt-in for external and internal late-stage NMEs

2017 launch in 4 indications including 11 molecules and 22 first-in-disease combinations

CIT=cancer immunotherapy; IND=new investigational drug application; NME=new molecular entity; LIP=late-stage investment point; SOC=standard of care

Late-stage oncology pipeline

Phase III studies about to start - new indications added

Lung: NSCLC, SCLC, ALK+NSCLC

2/3L	Tec	OAK, FIR ✓
1L non-sq	Tec+carbo/pac+/-Avastin	IMpower150
1L non-sq	Tec+carbo+nab-pac	IMpower130
1L sq	Tec+carbo+pac/nab-pac	IMpower131
1L non-sq	Tec+cis/carbo+pem	IMpower132
1L Dx+	Tec	IMpower110
Adj	Tec	IMpower010
1L SCLC	Tec+carbo+etoposide	IMpower133
1L ALK+	Alecensa	ALEX

Melanoma

Adj	Zelboraf	
1L BRAFwt	Tec+Cotellic	IMspire170
1L BRAFmut	Tec+Cotellic+Zelboraf	IMspire150

Renal

1L	Tec+/-Avastin	IMmotion150
1L	Tec+Avastin	IMmotion151
Adj	Tec	IMmotion010

Bladder

1L/2L+	Tec	IMvigor210 ✓
1L	Tec	IMvigor210
2L+	Tec	IMvigor211
1L	Tec+/-gem/plat	IMvigor130
Adj MIBC	Tec	IMvigor010



Ph3 studies to start

Breast: TNBC; HER2+; ER+/HER2-

1L TNBC	Tec+nab-pac	IMpassion130
1L TNBC	Tec+pac	IMpassion131
Neoadj TNBC	Tec+nab-pac	IMpassion031
Adj HER2+	Perjeta+Herceptin	APHINITY
ER+/HER2-	taselisib+fulvestrant	

Colorectal

3L	Tec+Cotellic	IMblaze370

Prostate

1L	ipatasertib	
2/3L	Tec+enzalutamide	IMbassador250

Ovarian

Front-line	Tec+/-carbo/pac/Avastin	IMaGYN050

Hematology: CLL, MM, AML

1L CLL	Venclexta*+Gazyva	CLL14
R/R CLL	Venclexta*+Rituxan	MURANO
R/R MM	Venclexta*+bortezomib/dexa	BELLINI
AML	idasanutlin	
1L AML	Venclexta*+azacitidine	
tba		

Tec=Tecentriq; *Venclexta in collaboration with AbbVie; carbo=carboplatin; pac=paclitaxel; nab-pac=nab-paclitaxel; cis=cisplatin; pem=pemetrexed; gem=gemcitabine; plat=platinum; dexa=dexamethasone; tba=to be announced

2016 results

Innovation

Outlook

2017 onwards: Key data read-outs



Outcome studies are event-driven: timelines may change

2017: Key late-stage news flow

	Compound	Indication	Milestone
Regulatory	**Alecensa**	2L ALK+ NSCLC	EU approval
	Ocrevus	RMS / PPMS	US/EU launch
	Tecentriq	1L Bladder cancer cis-ineligible	US approval
	Tecentriq	2/3L NSCLC and 2L Bladder cancer	EU approval
	Gazyva	1L FL (iNHL)	US/EU filing
	Actemra	Giant cell arteritis	US/EU approval
	emicizumab	Hemophilia A inhibitors	US/EU filing
Phase III readouts*	**Perjeta + Herceptin**	Adjuvant HER2+ BC	Ph III APHINITY
	Alecensa	1L ALK+ NSCLC	Ph III ALEX
	Venclexta + Rituxan	R/R CLL	Ph III MURANO
	Tecentriq + chemo/ Tecentriq + chemo + Avastin	1L NSCLC	Ph III IMpower150
	lampalizumab	Geographic atrophy	Ph III SPECTRI and CHROMA
	emicizumab	Hemophilia A non-inhibitors	Ph III HAVEN3

* Outcome studies are event-driven: timelines may change

Diagnostics Division

Roland Diggelmann

CEO Roche Diagnostics

2016: Diagnostics Division sales

Strong growth in laboratory businesses

	2016 CHFm	2015 CHFm	Change in % CHF	Change in % CER
Diagnostics Division	**11,473**	**10,814**	**6**	**7**
Centralised and Point of Care Solutions	6,698	6,175	8	9
Diabetes Care	2,016	2,128	-5	-4
Molecular Diagnostics	1,845	1,719	7	7
Tissue Diagnostics	914	792	15	14

CER=Constant Exchange Rates
Underlying growth of Molecular Diagnostics excluding sequencing business: +3%

2016: Diagnostics Division regional sales

Growth driven by all regions



+19% growth in E7 countries[2]

[1] Europe, Middle East and Africa; [2] Brazil, China, India, Mexico, Russia, South Korea, Turkey
All growth rates at Constant Exchange Rates

2016: Diagnostics Division highlights
Growth driven by immunodiagnostic products



- Driven by immunodiagnostics (+13%) and clinical chemistry (+6%)
- Spill-over of US reimbursement cuts to private sector
- Virology (+9%) and blood screening (+5%)
- Advanced staining portfolio (+9%); primary staining (+21%)

[1] Underlying growth of Molecular Diagnostics excluding sequencing business: +3%
CER=Constant Exchange Rates; EMEA=Europe, Middle East and Africa

2016: Diagnostics Division

Core operating profit growth impacted by new product launches and Diabetes Care

	2016 CHFm	2016 % sales
Sales	**11,473**	**100.0**
Royalties & other op. inc.	116	1.0
Cost of sales	-5,294	-46.1
M & D	-2,645	-23.1
R & D	-1,327	-11.6
G & A	-402	-3.5
Core operating profit	**1,921**	**16.7**

2016 vs. 2015 CER growth



-1% in CHF

CER=Constant Exchange Rates

Implementing the fully connected core laboratory



Connecting disciplines
(cobas 6800/8800, cobas 6500, cobas p 612)

Highest throughput analysers
(cobas e 801, cobas c 702)

Comprehensive menu
(Procalcitonin; Zika; MPX; Syphilis; EGFR v2)

Digitalised data management

Seamless workflow and laboratory IT
(cobas connection modules)

Continued strong growth in SWA* in all regions

Expansion of menu:

- Procalcitonin test: FDA approved
- Syphilis test: FDA approved
- Chagas test: CE mark
- TnT Gen 5 test: FDA approved

190 cobas e 801 instruments installed



* SWA = serum work area: clinical chemistry and immunodiagnostics

Launch of cobas m 511 hematology analyser

Preparation, staining and analysis in one system

All-in-one:
Hematology analyser + slide maker/stainer
+ digital morphologic analyser

Unique slide-making process		Clear, consistent cell distribution
Low sample volume (30 µL)		Convenient for paediatric and oncology patients
Digital multi-spectral imaging		Unique cell counting and classification

cobas 6800/8800 driving growth in molecular

Main menu completion

Blood Screening	Infectious Diseases	Women's Health
MPX	HIV-1	HPV
WNV	HBV, HCV	CT/NG
DPX	CMV	TV/MG
HEV (Not available in the US)	HIV-1/2 Qual	
Zika (IND)	MTB	
Zika (US-IVD)	MAI	
chikV/denV	RIF/INH	

Installed instrument base: 258

Launched in 2016
Launch planned in 2017
Launch planned in 2018

MPX – Multiplex detection of HIV-1, HIV-2, HCV and HBV; WNV - West Nile virus; DPX – duplex detection of parvovirus B19 and HAV; HEV - Hepatitis E virus; ChikV - chikungunya virus; DenV - Dengue virus; CMV – Cytomegalovirus; MTB - Mycobacterium tuberculosis; MAI - Mycobacterium avium-intracellulare infection; RIF – rifampicin; INH – isoniazid (detection of RIF/INH resistance in MTB positive samples); TV - Trichomonas vaginalis; MG - Mycoplasma genitalium

Accu-Chek Guide System

Cloud based technology with universal technology platform

- Advanced accuracy
- Wireless connectivity
- CE mark in Q3 2016
- US launch in Q1 2017

Key launches 2016

	Area	Product	Market
Instruments/ Devices	Central Laboratory	cobas 8000 <e 801> – high throughput immunochemistry analyser	EU ✓
		cobas c 513 – high throughput dedicated HbA1c analyser	US ✓
	Point of Care	CoaguChek INRange (Zenith) – modified analyser for intuitive self testing with full blue tooth connectivity	EU ✓
	Sequencing	Roche SMRT Sequencer – single molecule sequencer for clinical research (in collaboration with Pacific Biosciences)	WW ✗
	Diabetes Care	Accu-Chek Guide – next-generation blood glucose monitoring system	EU ✓
		Accu-Chek Insight CGM – new high-performance continuous glucose monitoring system	EU ✓
Tests/ Assays	Virology	cobas 6800/8800 HIV Qual – early Infant Diagnosis and Confirmatory HIV Test	EU
	HPV/Microbiology	cobas 6800/8800 CT/NG – fully automated solution for screening and diagnosis of *Chlamydia trachomatis and Neisseria gonorrhoeae in symptomatic & asymptomatic patients*	EU ✓
	Point of Care	cobas Liat Influenza A/B plus RSV (CLIA) – automated multiplex real time RT-PCR assay for qualitative detection and discrimination of Influenza A virus, Influenza B virus and respiratory syncytial virus (RSV)	US ✓
	Sequencing	ctDNA oncology panels – liquid biopsy for circulating tumor DNA for cancer therapy selection	US
	Companion Diagnostics	PD-L1 (SP142) for Bladder Cancer* – complementary diagnostic for Tecentriq	US ✓
		PD-L1 (SP142) for NSCLC* – complementary diagnostic for Tecentriq	US ✓

2017 Diagnostics: An important year for our pipeline

Key platform launches



Launch dates depend on development outcome; timelines may change

Key launches 2017

	Area	Product	Market
Instruments/ Devices	**Central Laboratory**	cobas 8000 <e 801> – High throughput immunochemistry analyser	US
		CCM High Speed – for up to 6000 samples/hour	WW
	Coagulation Testing	cobas t 511 / t 711 – Medium and high volume coagulation systems	EU
	Point of Care	CoaguChek Vantus – Hand-held coagulation monitoring system for Patient Self-Testing	US
	Diabetes Care	Accu-Chek Instant bG System	EU
Tests/ Assays	**HPV**	cobas HPV – Next generation HPV DNA test leveraging 68/8800 Automation to detect 14 hrHPV with simultaneous detection of genotypes 16 and 18	EU
		CINtec Histology – Diagnostic component of the Roche Cervical Cancer portfolio	US
	Virology	cobas HIV 1&2 Qual – For use on the cobas 6800/8800 Systems; for diagnosis of acute HIV 1 or 2 infection and for confirmation of HIV 1 or 2 infection	EU
	Sequencing	AVENIO ctDNA panels - Liquid biopsy for circulating tumor DNA, 3 panels: targeted panel (17 genes for cancer therapy selection), expanded panel (77 genes for cancer therapy selection), surveillance panel (197 genes)	EU/US
	cobas Liat	cobas Liat C.diff – Qualitative IVD test, that utilises real-time PCR, for the direct detection of the tcdB gene of toxigenic *C. difficile* in unformed stool specimens	EU
		cobas Liat MRSA/SA – Qualitative IVD test, that utilises real-time PCR, for the direct detection of MRSA and *Staphylococcus aureus* DNA from nasal swabs	EU
	Women's Health	AMH – Immunoassay for the in vitro quantitative determination of anti-Mullerian hormone (AMH) in human serum and plasma for the assessment of the ovarian reserve in women presenting to fertility clinics	US
	Companion Diagnostics	PD-L1 (SP142) for Bladder Cancer* – complementary diagnostic for Tecentriq	EU
		PD-L1 (SP142) for NSCLC* – complementary diagnostic for Tecentriq	EU

* Achieve commercial readiness, dependent on Pharma label and approval

Finance

Alan Hippe

Chief Financial Officer

2016: Highlights

Business

- Good sales growth of +4%[1] and Core EPS growth +5%[1] (+2%[1] excluding PSI*)
- Core operating profit up +4%[1]
- Dividend in Swiss francs further increased

Cash flow

- Cash generation remains strong (Operating FCF of CHF 14.1bn) despite higher investments in PP&E** and intangible assets
- Accounts receivable in Southern Europe further decreased

Net financial results

- Continued use of attractive financing conditions in capital markets for debt restructuring
  - Total issuance of USD 2.5bn and EUR 0.65bn
  - Total redemptions of USD 1.54bn and EUR 2.1bn
- Loss on early bond redemption of CHF 142m (vs CHF 79m[2] in 2015), lower interest expenses of CHF 180m (down 20%[1] vs 2015), lower FX losses

[1] At Constant Exchange Rates (CER); [2] Does not include a major debt restructuring pre-tax loss of CHF 381m included in the IFRS result; *PSI=Past Service Income; **Property, plant and equipment

2016: Group performance

*Core EPS growth +5%, +2% excluding PSI**

	2016 CHFm	2015 CHFm	Change in % CHF	Change in % CER	Excl. PSI*
Sales	**50,576**	**48,145**	**5**	**4**	
Core operating profit	**18,420**	**17,542**	**5**	**4**	**2**
as % of sales	*36.4*	*36.4*			
Core net income	**12,688**	**11,837**	**7**	**7**	**4**
as % of sales	*25.1*	*24.6*			
Core EPS (CHF)	**14.53**	**13.49**	**8**	**5**	**2**
IFRS net income	**9,733**	**9,056**	**7**	**7**	
Operating free cash flow	**14,086**	**14,872**	**-5**	**-7**	
as % of sales	*27.9*	*30.9*			
Free cash flow	**9,130**	**10,306**	**-11**	**-14**	
as % of sales	*18.1*	*21.4*			

CER=Constant Exchange Rates
* Past Service Income; growth rates at CER

2016: Group operating performance

Core operating profit growth +4%

	2016 CHFm	2016 abs. CHFm
Sales	**50,576**	**+2,431**
Royalties & other op. inc.	2,060	-198
Cost of sales	-13,469	-763
M & D	-9,007	-397
R & D	-9,915	-583
G & A	-1,825	+388
Core operating profit	**18,420**	**+878**

PSI*=+426



CER=Constant Exchange Rates
* Past Service Income

2016: Core operating profit and margin at high levels



[1] At CER=Constant Exchange Rates

Numerous productivity efforts under way

	Pharmaceuticals	Diagnostics	Group
Cost of sales	Lean manufacturing		
Marketing and distribution	Resource shift to support launches	Prioritisation to support launches	
Research and development	Speed & agility Strict prioritisation	Speed & agility Strict prioritisation	R&D cost benchmarking
General and administration	Shared Service Centers		

Full Year 2016: Core net financial result

Positive impact from debt restructuring



CER = Constant Exchange Rates (avg full year 2015)

[1] incl. amortisation of debt discount and net gains on interest rate derivatives

2016: Stable Group Core tax rate



Balance sheet 31 December 2016

Net debt to assets decreased to 17%



CER = Constant Exchange Rates (avg full year 2015)

2016: Operating free cash flow impacted by investments into PP&E[1] and intangible assets



[1] Property, plant and equipment; [2] Net working capital; [3] Intangible Assets; CER=Constant Exchange Rates (avg full year 2015)

2016: Accounts receivable in Southern Europe further decreased



Sovereign country ratings from Standard & Poor's, as of 6 Jan 2017

2016: Group net debt improved despite higher investments



CER = Constant Exchange Rates (avg full year 2015)

Exchange rate impact on sales growth

Positive impact from USD, JPY and EUR



CER = Constant Exchange Rates (avg full year 2015)

Low currency impact in 2016





In 2016 impact is (%p):

	Q1	HY	Sep YTD	FY
Sales	1	1	2	1
Core operating profit		2		1
Core EPS		2		3

*In 2017 currency impact[1] expected is (based on **31 Dec 2016** FX rates):*

- Between 0 and +2%p FX impact on sales, Core OP and Core EPS

[1] On Group growth rates

2017 outlook

Group sales growth[1]	Low to mid-single digit
Core EPS growth[1]	Broadly in line with sales growth
Dividend outlook	Further increase dividend in Swiss francs

[1] At Constant Exchange Rates (CER)

Pipeline summary

Changes to the development pipeline
FY 2016 update

New to Phase I

4 NMEs:
RG6107 C5 inh MAb - PNH
RG6114 mPI3K alpha inh – HR+ BC
RG7854 TLR7 agonist (3) – HBV
RG7907 HBV Capsid (2) – HBV

1 NME in-licensed (Hanmi):
RG6185 pan-RAF inh – oncology

1 NME in-licensed (BioNTech):
RG6180 personalised cancer vaccine – oncology

1 NME with ownership transfer to Chugai:
RG7304 now displayed as **CHU**

1 NME added by Chugai:
CHU Glypican-3/CD3 biMAb – solid tumours

New to Phase II

2 NMEs transitioned from Ph1:
RG6125 Cadherin-11 MAb – RA
RG7916 SMN2 splicer (2) – SMA

Ipatasertib indications specified:
1 NME:
RG7440 ipatasertib – CRPC
2 AIs:
RG7440 ipatasertib – 1L TNBC
RG7440 ipatasertib – TNBC neoadj

1 opt-in deal signed:
NOV TLR4 MAb – autoimmune diseases

New to Phase III

5 AIs:
RG3645 Lucentis 0.3mg PFS - DME
RG7421 Cotellic + Tecentriq + Zelboraf – BRAF mut-positive melanoma
RG7446 Tecentriq + enzalutamide – CRPC
RG7446 Tecentriq - RCC adj

RG6013 emicizumab - Q4W in hemophilia A

New to Registration

3 AIs:

RG1569 Actemra – giant cell arteritis (EU/US)
RG7159 Gazyva – 1L FL (EU)
RG3645 Lucentis – diabetic retinopathy w/o DME (US)

Added to 2L mUC entry:
RG7446 Tecentriq – 1L cis-ineligible mUC

1 AI filed by Chugai:
CHU Actemra – large-vessel vasculitis

Removed from Phase I

2 NMEs:
RG7841 Ly6E ADC – solid tumours
RG7893 Nav1.7 inh – pain

Removed from Phase II

2 AIs:
RG3502 Kadcyla – HER2+ NSCLC
RG7604 taselisib – 2L sq NSCLC

Removed from Phase III

Removed from Registration

1 AI following FDA approval:
RG3645 Lucentis – myopic CNV

Status as of 1 February 2017

Roche Group development pipeline

Phase I (42 NMEs + 26 AIs)

RG6016	LSD1 inh	SCLC
RG6047	SERD (2)	ER+ (HER2-neg) mBC
RG6058	TIGIT ± Tecentriq	solid tumours
RG6061	HIF1 alpha LNA	solid tumours
RG6078	IDO inh	solid tumours
	IDO inh + Tecentriq	solid tumours
RG6114	mPI3K alpha inh	HR+ BC
RG6146	BET inh	solid + heme tumours
RG6180	personalised cancer vaccine	oncology
RG6185	pan-RAF inh	oncology
RG7155	emactuzumab + Tecentriq	solid tumours
	emactuzumab + CD40 iMAb	solid tumours
RG7159	anti-CD20 multiple combos	heme tumours
RG7386	FAP-DR5 biMAb	solid tumours
RG7421	Cotellic + Tecentriq + Avastin	2/3L CRC
RG7446	Tecentriq	solid tumours
	Tecentriq	NMIBC
	T + Zelboraf ± Cotellic	melanoma
	T ± Avastin ± chemo	HCC, GC, PaC
	T ± Avastin ± chemo	solid tumours
	T + Cotellic	solid tumours
	T + ipi/IFN	solid tumours
	T + Tarceva or Alecensa	NSCLC
	T + anti-CD20 multiple combos	lymphoma
	T ± lenalidomide ± daratumumab	MM
	T + K/HP	HER2+ BC
	T ± azacitidine	MDS
	T + radium 223	mCRPC
	T + guadecitabine	AML
RG7461	FAP IL2v FP	solid tumours
RG7601	Venclexta multiple combos	NHL
	Venclexta + Gazyva	CLL
	Venclexta + Cotellic/idasanutlin	AML
RG7741	ChK1 inh	solid tumours
RG7802	CEA CD3 TCB ± Tecentriq	solid tumours
RG7813	CEA* IL2v FP + Tecentriq	solid tumours
RG7828	CD20/CD3 TDB	heme tumours
RG7876	CD40 iMAb + Tecentriq	solid tumours
	CD40 iMAb + vanucizumab	solid tumours
RG7882	ADC	ovarian cancer
RG7888	OX40 MAb	solid tumours
	OX40 MAb + Tecentriq	solid tumours
RG7986	ADC	r/r NHL
CHU	Raf/MEK dual inh	solid tumours
CHU	glypican-3/CD3 biMAb	solid tumours
RG3616	Erivedge + Esbriet	IPF
	Erivedge + ruxolitinib	myelofibrosis
RG6069	anti-fibrotic agent	Fibrosis
RG6107	C5 inh MAb	PNH
RG7159	obinutuzumab	renal transplant
RG7880	IL-22Fc	inflammatory diseases
RG7990	-	asthma
RG6080	DBO β-lactamase inh	bacterial infections
RG7834	-	HBV
RG7854	TLR7 agonist (3)	HBV
RG7861	anti-*S. aureus* TAC	infectious diseases
RG7907	HBV Capsid (2)	HBV
RG7992	FGFR1/KLB MAb	metabolic diseases
RG6000	-	ALS
RG6029	Nav1.7 inh (2)	pain
RG6100	Tau MAb	Alzheimer's
RG7203	PDE10A inh	schizophrenia
RG7800	SMN2 splicer	SMA
RG7906	-	psychiatric disorders
RG7935	α-synuclein MAb	Parkinson's
IONIS	ASO	Huntington's
CHU	PTH1 receptor agonist	hypoparathyroidism
CHU	-	hyperphosphatemia

New Molecular Entity (NME)
Additional Indication (AI)
Oncology
Immunology
Infectious Diseases
CardioMetabolism
Neuroscience
Ophthalmology
Other

RG-No Roche/Genentech
CHU Chugai managed
IONIS IONIS managed
PRO Proximagen managed
NOV Novimmune managed

*INN: cergutuzumab amunaleukin
**Ph3 in preparation
***out-licensed to Galderma and Maruho
T=Tecentriq

Phase II (22 NMEs + 12 AIs)

RG3502	Kadcyla + Tecentriq	2L HER2+ mBC
RG6046	SERD	ER+ (HER2-neg) mBC
RG7221	vanucizumab	mCRC
RG7421	Cotellic + Tecentriq ± taxane	TNBC
RG7440	ipatasertib**	CRPC
	ipatasertib	1L TNBC
	ipatasertib	TNBC neoadj
RG7596	polatuzumab vedotin	heme tumours
RG7601	Venclexta + Rituxan	DLBCL
	Venclexta + Rituxan	r/r FL
RG7604	taselisib + letrozole	(HER2-neg) BC neoadj
RG7686	codrituzumab	liver cancer
RG3637	lebrikizumab	atopic dermatitis
	lebrikizumab	COPD
	lebrikizumab ± Esbriet	IPF
RG6125	Cadherin-11 MAb	RA
RG6149	ST2 MAb	asthma
RG7159	obinutuzumab	lupus
RG7625	Cat-S antag	autoimmune diseases
RG7845	BTK inh	autoimmune diseases
CHU	nemolizumab***	atopic dermatitis
CHU	nemolizumab	pruritus in dialysis pts
PRO	VAP-1 inh	inflammatory disease
NOV	TLR4 MAb	autoimmune diseases
RG6152	CAP endonuclease inh	influenza
RG7227	danoprevir	HCV
RG7745	Flu A MAb	influenza A
CHU	URAT1 inh	gout
RG1662	basmisanil	CIAS
RG6083	olesoxime	SMA
RG7314	V1 receptor antag	autism
RG7916	SMN2 splicer(2)	SMA
RG3645	ranibizumab PDS	wAMD
RG7716	VEGF-ANG2 biMAb	wAMD, DME

Status as of 1 February 2017

Roche Group development pipeline

Phase III (8 NMEs + 33 AIs)

RG435	Avastin[1]	1L GBM
	Avastin	mesothelioma
RG1273	Perjeta + Herceptin	HER2+ BC adj
	Perjeta + Herceptin	HER2+1L gastric ca
RG3502	Kadcyla	HER2+ BC adj
	Kadcyla + Perjeta	HER2+ BC adj
RG6013	emicizumab	hemophilia A, FVIII inh
	emicizumab	pediatric hemophilia A, FVIII inh
	emicizumab	hemophilia A, w/o FVIII inh
	emicizumab	Q4W hemophilia A
RG7204	Zelboraf	BRAFmut melanoma adj
RG7388	idasanutlin	AML
RG7421	Cotellic + Tecentriq	3L CRC
	Cotellic + T + Zelboraf	BRAFmut melanoma
RG7446	Tecentriq	NSCLC adj
	Tecentriq	MIBC adj
	T + Abraxane	1L non-sq NSCLC
	T + chemo + Avastin	1L non-sq NSCLC
	T + chemo + pemetrexed	1L non-sq NSCLC
	T + Abraxane	1L sq NSCLC
	T + Abraxane	TNBC
	T + Avastin	RCC
	T ± chemo	1L mUC
	T + chemo	1L extensive stage SCLC
	T + enzalutamide	CRPC
	Tecentriq Dx+	1L sq + non-sq SCLC
	Tecentriq	RCC adj
RG7601	Venclexta + Rituxan	r/r CLL
	Venclexta + Gazyva	1L CLL
	Venclexta + bortezomib	MM
RG7604	taselisib + fulvestrant	ER+(HER2-neg) mBC
RG7853	Alecensa	1L ALK+ NSCLC
RG105	MabThera	pemphigus vulgaris
RG1569	Actemra	systemic sclerosis
RG7413	etrolizumab	ulcerative colitis
	etrolizumab	Crohn's disease
RG1450	gantenerumab	Alzheimer's disease
RG6168	IL-6R MAb	neuromyelitis optica
RG7412	crenezumab	Alzheimer's disease
RG7417	lampalizumab	geographic atrophy
RG3645	Lucentis 0,3mg PFS[1]	DME

Registration (3 NMEs + 7 AIs)

RG105	MabThera SC[2]	CLL, NHL
RG435	Avastin[3]	rel. ovarian ca. Pt-sensitive
RG7159	Gazyva[4]	1L FL
RG7446	Tecentriq[5]	1L cis-ineligible + 2L mUC
	Tecentriq[6]	2L+ NSCLC
RG7853	Alecensa[7]	2L ALK+ NSCLC
RG1569	Actemra	giant cell arteritis
CHU	Actemra	large-vessel vasculitis
RG1594	OCREVUS®	PPMS, RMS
RG3645	Lucentis[1]	diabetic retinopathy w/o DME

1. US only
2. Approved in EU – Filed in US
3. Approved in US, filed in EU for chemo backbone extension
4. Filed in EU
5. Filing based on IMvigor210 approved in US for 2L, filed in US for 1L, phase 3 ongoing
6. Approved in US
7. Approved in US and Japan

New Molecular Entity (NME)
Additional Indication (AI)
Oncology
Immunology
Infectious Diseases
CardioMetabolism
Neuroscience
Ophthalmology
Other

RG-No Roche/Genentech
CHU Chugai managed
RG105 Branded as Rituxan (US, Japan)
RG1569 Branded as RoActemra (EU)
RG7159 Branded as Gazyvaro (EU)
RG-No Roche/Genentech
CHU Chugai managed
T=Tecentriq

Status as of 1 February 2017

NME submissions and their additional indications

Projects currently in phase 2 and 3



Unless stated otherwise, submissions are planned to occur in US and EU

✓indicates a submission which has occurred with regulatory action pending ; *approved in US

New Molecular Entity (NME)
Additional Indication (AI)
Oncology
Immunology
Infectious Diseases
CardioMetabolism
Neuroscience
Ophthalmology
Other

Status as of 1 February 2017

AI submissions for existing products

Projects currently in phase 2 and 3

2016

RG3645	**Lucentis** Diabetic retinopathy w/o DME ✓
RG3645	**Lucentis 0.5mg PFS (US)[1]** AMD, RVO ✓
RG3645	**Lucentis (US)[1]** Myopic CNV ✓
RG1569	**Actemra** Giant cell arteritis ✓
RG435	**Avastin[2]** Rel. Pt-sens. ovarian cancer ✓
RG7159	**Gazyva (EU)** 1L FL ✓
RG7446	**Tecentriq[1]** 2L+ NSCLC ✓
RG7446	**Tecentriq (US)** 1L cis-ineligible bladder cancer ✓

2017

RG3645	**Lucentis 0.3mg PFS (US)[1]** DME
RG435	**Avastin (US)** GBM
RG435	**Avastin** Mesothelioma
RG1273	**Perjeta + Herceptin** 1L HER2+ gastric cancer
RG1273	**Perjeta + Herceptin** HER2+ BC adj.
RG7159	**Gazyva (US)** 1L FL
RG7204	**Zelboraf** Melanoma adj.
RG7601	**Venclexta + Rituxan** r/r CLL
RG7853	**Alecensa** 1L Alk+ NSCLC

2018

RG105	**MabThera** Pemphigus vulgaris
RG1569	**Actemra** Systemic sclerosis
RG7446	**Tecentriq + chemo** 1L extensive stage SCLC
RG7446	**Tecentriq + chemo + Avastin** 1L non-sq NSCLC
RG7446	**Tecentriq + Abraxane** 1L sq NSCLC
RG7446	**Tecentriq + Abraxane** 1L non-sq NSCLC
RG7446	**Tecentriq + Avastin** RCC
RG7446	**Tecentriq + Abraxane** TNBC

2019 and beyond

RG3502	**Kadcyla + Tecentriq** 2L Her2+ mBC
RG3502	**Kadcyla + Perjeta** HER2+ BC adj.
RG3502	**Kadcyla** HER2+ BC adj.
RG7446	**Tecentriq** 1L non-sq + sq NSCLC (Dx+)
RG7446	**Tecentriq + enzalutamide** CRPC
RG7601	**Venclexta + Rituxan** r/r FL
RG7601	**Venclexta + Gazyva** 1L CLL
RG7601	**Venclexta + bortezomib** MM
RG7601	**Venclexta + Rituxan** DLBCL
RG3502	**Kadcyla + Tecentriq** 2L Her2+ mBC
RG3645	**ranibizumab PDS** wAMD
RG7159	**obinutuzumab** Lupus nephritis
RG7421	**Cotellic + Tecentriq** 3L CRC
RG7421	**Cotellic + Tecentriq + Zelboraf** BRAFmut melanoma
RG7421	**Cotellic + Tecentriq ± taxane** TNBC
RG7446	**Tecentriq + chemo + pemetrexed** 1L non-sq NSCLC
RG7446	**Tecentriq ± chemo** 1L mUC
RG7446	**Tecentriq** NSCLC adj
RG7446	**Tecentriq** MIBC adj
RG7446	**Tecentriq** RCC adj

✓ indicates submission to health authorities has occurred
1 Approved in US
2 Approved in EU
Unless stated otherwise, submissions are planned to occur in US and EU.

New Molecular Entity (NME)
Additional Indication (AI)
Oncology
Immunology
Infectious Diseases
CardioMetabolism
Neuroscience
Ophthalmology
Other

Status as of 1 February 2017

Major granted and pending approvals 2016

	US		EU		Japan-Chugai	
Approved	RG7604	**Venclexta 17p del** r/r CLL April 2016	RG105	**MabThera SC** CLL June 2016	CHU	**Bonviva** Osteoporosis (oral) January 2016
	RG7446	**Tecentriq** 2L mUC May 2016	RG435	**Avastin + Tarceva** EGFRmut NSCLC June 2016	CHU	**Avastin** Cervical cancer May 2016
	RG7446	**Tecentriq** 2L+ NSCLC October 2016	RG7159	**Gazyva** Rituximab-ref. iNHL June 2016		
	RG7159	**Gazyva** Rituximab-ref. iNHL February 2016				
	RG435	**Avastin** Rel. Pt-sens. ovarian ca. December 2016				
	RG3645	**Lucentis 0.5mg PFS** AMD, RVO October 2016				
	RG3645	**Lucentis** mCNV January 2017				
Pending approval	RG7446	**Tecentriq** 1L cis-ineligible bladder ca. Filed October 2016	RG7853	**Alecensa** 2L ALK+ NSCLC Filed September 2015	CHU	**Actemra** Large-vessel vasculitis Filed November 2016
	RG1569	**Actemra** Giant cell arteritis Filed November 2016	RG7446	**Tecentriq** 2L mUC Filed April 2016		
	RG1594	**OCREVUS®** PPMS & RMS Filed April 2016	RG7446	**Tecentriq** 2L+ NSCLC Filed April 2016		
	RG3645	**Lucentis** Diabetic retinopathy w/o DME Filed October 2016	RG7159	**Gazyva** 1L follicular lymphoma Filed October 2016		
			RG1569	**Actemra** Giant cell arteritis Filed November 2016		
			RG1594	**OCREVUS®** PPMS & RMS Filed April 2016		

New Molecular Entity (NME)
Additional Indication (AI)
Oncology
Immunology
Infectious Diseases
CardioMetabolism
Neuroscience
Ophthalmology
Other

Status as of 1 February 2017

Roche Group Development pipeline
Combinations

Phase I (5 NMEs + 22 AIs)

RG6058	TIGIT ± Tecentriq	solid tumours
RG6078	IDO inh +Tecentriq	solid tumours
RG7155	Emactuzumab + Tecentriq	solid tumours
	Emactuzumab + CD40 iMAb	solid tumours
RG7159	anti-CD20 multiple combos	heme tumours
RG7421	Cotellic + Tecentriq + Avastin	2/3L CRC
RG7446	T + Zelboraf ± Cotellic	melanoma
	T ± Avastin ± chemo	HCC, GC, PaC
	T ± Avastin ± chemo	solid tumours
	T + Cotellic	solid tumours
	T + ipi/IFN	solid tumours
	T + Tarceva or Alecensa	NSCLC
	T + anti-CD20 multiple combos	lymphoma
	T ± lenalidomide ± daratumumab	MM
	T + K/HP	HER2+ BC
	T + azacitidine	MDS
	T + radium 223	mCRPC
RG7601	Venclexta multiple combos	NHL
	Venclexta + Gazyva	CLL
	Venclexta + Cotellic/idasanutlin	AML
RG7802	CEA CD3 TCB ± Tecentriq	solid tumours
RG7813	CEA* IL2v FP + Tecentriq	solid tumours
RG7876	CD40 iMAb + Tecentriq	solid tumours
	CD40 iMAb + vanucizumab	solid tumours
RG7888	OX40 Mab + Tecentriq	solid tumours
RG3616	Erivedge + Esbriet	IPF
	Erivedge + ruxolitinib	myelofibrosis

Phase II (6 AIs)

RG3502	Kadcyla + Tecentriq	2L HER2+ mBC
RG7421	Cotellic + Tecentriq ± taxane	TNBC
RG7601	Venclexta + Rituxan	DLBCL
	Venclexta + Rituxan	r/r FL
RG7604	taselisib + letrozole	(HER2-) BC neoadj
RG3637	Lebrikizumab ± Esbriet	IPF

Phase III (1 NMEs + 17 AIs)

RG1273	Perjeta + Herceptin	HER2+ BC adj
	Perjeta + Herceptin	1L HER2+ gastric ca
RG3502	Kadcyla + Perjeta	HER2+ BC adj
RG7421	Cotellic + Tecentriq	3 L CRC
	Cotellic + T + Zelboraf	BRAFm melanoma
RG7446	T + Abraxane	1L non-sq NSCLC
	T + chemo + Avastin	1L non-sq NSCLC
	T + chemo + pemetrexed	1L non-sq NSCLC
	T + Abraxane	1L sq NSCLC
	T + Abraxane	TNBC
	T + Avastin	RCC
	T ± chemo	1L mUC
	T + chemo	1L extensive stage SCLC
	T + enzalutamide	CRPC
RG7601	Venclexta + Rituxan	r/r CLL
	Venclexta + Gazyva	1L CLL
	Venclexta + bortezomib	MM
RG7604	taselisib + fulvestrant	ER+ (HER2-neg) mBC

New Molecular Entity (NME)
Additional Indication (AI)
Oncology
Immunology

RG-No Roche/Genentech
CHU Chugai managed

*INN: cergutuzumab amunaleukin
T=Tecentriq

Status as of 1 February 2017

Cancer immunotherapy pipeline overview

Phase I (10 NMEs + 28 AIs)

RG6058	TIGIT ± Tecentriq	solid tumours
RG6078	IDO inh	solid tumours
	IDO inh + Tecentriq	solid tumours
RG6180	personalised cancer vaccine	oncology
RG7155	emactuzumab + Tecentriq	solid tumours
	emactuzumab + CD40 iMAb	solid tumours
RG7421	Cotellic + Tecentriq + Avastin	2/3L CRC
RG7446	Tecentriq	solid tumours
	Tecentriq	NMIBC
	T + Zelboraf ± Cotellic	melanoma
	T ± Avastin ± chemo	HCC, GC, PaC
	T ± Avastin ± chemo	solid tumours
	T + Cotellic	solid tumours
	T + Ipi/IFN	solid tumours
	T + Tarceva/Alecensa	NSCLC
	T + anti-CD20 multiple combos	lymphoma
	T ± lenalidomide ± daratumumab	MM
	T + K/HP	HER2+ BC
	T + azacitidine	MDS
	T + radium 223	mCRPC
	T + guadecitabine	AML
RG7461	FAP IL2v FP	solid tumours
RG7802	CEA CD3 TCB ± Tecentriq	solid tumours
RG7813	CEA* IL2v FP + Tecentriq	solid tumours
RG7828	CD20/CD3 TDB	heme tumours
RG7876	CD40 iMAb + Tecentriq	solid tumours
	CD40 iMAb + vanucizumab	solid tumours
RG7888	OX40 iMAb	solid tumours
	OX40 iMAb + Tecentriq	solid tumours
INCY**	Tecentriq + IDO inh	solid tumours
CLDX**	Tecentriq + varlilumab	solid tumours
CRVS**	Tecentriq + CPI-4444	solid tumours
KITE**	Tecentriq + KTE-019	r/r DLBCL
AMGN**	Tecentriq + T-vec	TNBC, CRC
JNJ**	Tecentriq ± daratumumab	solid tumours
CLVS**	Tecentriq + rucaparib	ovarian ca
Epizyme**	Tecentriq + tazemetostat	r/r DLBCL
BioLine Rx**	Tecentriq + BL-8040	AML, solid tumours

Phase II (4 AIs)

RG3502	Kadcyla + Tecentriq	2L HER2+ mBC
RG7421	Cotellic + Tecentriq ± taxane	TNBC
IMDZ**	Tecentriq + NY-ESO-1	soft tissue sarcoma
SNDX**	Tecentriq + entinostat	TNBC

Phase III (15 AIs)

RG7421	Cotellic + Tecentriq	3L CRC
	Cotellic + T + Zelboraf	BRAFm melanoma
RG7446	Tecentriq	NSCLC adj
	Tecentriq	MIBC adj
	T + Abraxane	1L non-sq NSCLC
	T + chemo + Avastin	1L non-sq NSCLC
	T + chemo + pemetrexed	1L non-sq NSCLC
	T + Abraxane	1L sq NSCLC
	T + Abraxane	TNBC
	T + Avastin	RCC
	T ± chemo	1L mUC
	T + chemo	1L extensive stage SCLC
	T + enzalutamide	CRPC
	Tecentriq Dx+	1L sq + non-sq SCLC
	Tecentriq	RCC adj

Registration (1 NMEs + 1 AIs)

RG7446	Tecentriq[5]	1L cis-ineligible + 2L mUC
	Tecentriq[6]	2L+ NSCLC

1. Filing based on IMvigor210 approved in US for 2L, filed in US for 1L, phase 3 ongoing
2. Approved in US

New Molecular Entity (NME)
Additional Indication (AI)
Oncology

RG-No Roche/Genentech
*INN: cergutuzumab amunaleukin
T=Tecentriq

** External collaborations: INCY- Incyte INCB024360, CLDX - Celldex CD27 MAb; CLVS – Clovis PARPi, CRVS – Corvus CPI-444, KITE – Kite KTE-C19, AMGN – Amgen oncolytic virus (talimogene laherparapvec), JNJ – Janssen CD38 MAb., IMDZ – Immune Design CMB305, SNDX – Syndax HDACi

Status as of 1 February 2017

Doing now what patients need next